Literature DB >> 8903392

No association between genetic hemochromatosis and alpha1-antitrypsin deficiency.

S Fargion1, F Bissoli, A L Fracanzani, E Suigo, C Sergi, E Taioli, R Ceriani, V Dimasi, A Piperno, M Sampietro, G Fiorelli.   

Abstract

Genetic hemochromatosis and alpha1-antitrypsin (AAT) deficiency are frequent in white populations. Conflicting data on the association of the two conditions and on the severity of the disease in those in whom these disorders coexist have emerged from analyses of small numbers of patients. To determine if the frequency of AAT deficiency is increased in genetic hemochromatosis, we characterized this protein by isoelectric focusing and DNA analysis in 115 Italian patients with the disease and 290 controls. The frequency of AAT deficiency in patients with genetic hemochromatosis was similar to that in controls (10% and 9%, respectively). The prevalence of cirrhosis in patients with genetic hemochromatosis with MM phenotype was 53%, compared with 58% in those with non-MM phenotype; that of hepatocellular carcinoma, occurring only in cirrhotic patients, was 22% and 28%, respectively. In conclusion, the frequency of AAT deficiency was not increased in our large series of Italian patients with genetic hemochromatosis. Patients in whom the two defects coexisted did not appear to have a more severe disease, but the limited number of subjects with non-MM phenotype does not allow a conclusive evaluation of clinical differences between them and patients with genetic hemochromatosis with MM phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903392     DOI: 10.1002/hep.510240530

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease.

Authors:  Benedikt Schaefer; David Haschka; Armin Finkenstedt; Britt-Sabina Petersen; Igor Theurl; Benjamin Henninger; Andreas R Janecke; Chia-Yu Wang; Herbert Y Lin; Lothar Veits; Wolfgang Vogel; Günter Weiss; Andre Franke; Heinz Zoller
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

Review 2.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 3.  Epigallocatechin-3-Gallate Toxicity in Children: A Potential and Current Toxicological Event in the Differential Diagnosis With Virus-Triggered Fulminant Hepatic Failure.

Authors:  Consolato M Sergi
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

4.  Expression of hereditary hemochromatosis C282Y HFE protein in HEK293 cells activates specific endoplasmic reticulum stress responses.

Authors:  Matthew W Lawless; Arun K Mankan; Mary White; Michael J O'Dwyer; Suzanne Norris
Journal:  BMC Cell Biol       Date:  2007-07-24       Impact factor: 4.241

5.  Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Authors:  Paola Dongiovanni; Quentin M Anstee; Luca Valenti
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.